Pro Tip: Learn how to use HBI Alerts to follow your favorite topics

India

 

Dr Lal Pathlabs acquires two labs

India's largest diagnostics chain by revenue, NSE-listed Dr Lal Pathlabs, is acquiring two pathological laboratories for a total of around $1m (€900m).

Impact investor buys in Bangladesh as its LP sells Indian hospital stake

The Evercare Health Fund, formerly managed by now-defunct PE firm Abraaj, has made its first acquisition since TPG took over the fund last year, acquiring a private hospital group in Bangladesh for $120m. At the same time, UK development bank and Evercare investor CDC Group has partially sold a stake in an Indian hospital group, demonstrating you can make money while serving the low-end segment.

Investcorp bets on NephroPlus

Bahrain-based Investcorp has invested $45m in Indian dialysis provider NephroPlus in a deal which HBI estimates gives it a triple-digit-$m valuation. We talk to CEO Vikram Vuppala.

IHH takeover of Fortis on hold following Supreme Court ruling

Shares in under-fire Fortis, the large Indian hospital chain targeted by pan-Asian group IHH, dropped by almost 8% following a ruling by the Indian Supreme Court that Fortis' founders were guilty of contempt on Friday for not settling a debt, adding that similar proceedings against Fortis could follow. The IHH deal is now on hold. Could it be in jeopardy?

Former Abraaj health fund’s platform appoints new CEO

Evercare, part of what was formerly the Abraaj Growth Markets Health Fund (AGHF) and now managed by global PE firm TPG, has appointed a new CEO to oversee its hospitals and clinics in India, Pakistan, Kenya and Nigeria.

Interview: Abhay Soi, Chairman, Max Healthcare 

An outsider who doesn’t believe in “old answers” and wants to ‘’do things differently’’, Soi, 46, has big plans for the about-to-be-merged Max and Radiant businesses. The large Indian hospital chain is backed by private equity firm KKR-with 12 large and metro-based hospitals and 4 day-care centres, with 2019-20 expected sales of INR 4,200 crores (US$631m), making it second only to Apollo He talks exclusively to HBI about his plans and where he sees growth. 

Find Us